A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Low Density Lipoprotein (LDL) Cholesterol

Inclusion Criteria: * Male or female subjects ≥18 years of age * Previously untreated LDL cholesterol ≥100 mg/dL and ≤180 mg/dL. * Provide written informed consent. Exclusion Criteria: * Subjects with a medical condition requiring chronic pharmacological treatment * On direct questioning and physical examination have evidence of any clinically significant chronic disease, including known or suspected human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. * On direct questioning and physical examination have a medical history or evidence of abuse of drugs. * Medical history of gastrointestinal bleeding or gastric or duodenal ulcer. * Systolic pressure ≥140 mmHg or diastolic pressure \>89 mmHg requiring hypotensive medication. * Presence of secondary dyslipidemia. * Previous use of cholesterol lowering medication. * Previous coronary artery bypass graft (CABG). * Previous percutaneous transluminal coronary angioplasty (PTCA) with a drug-eluting stent. * Presence of severe congestive heart failure (New York Heart Classification \[NYHC\] III IV). * Presence of untreated or uncontrolled thyroid disease. * Past or current medical history of asthma or aspirin induced asthma * Previous hypersensitivity to ACE inhibitors (eg angioedema or cough). * Previous hypersensitivity to ARBs. * History of unstable angina. * Serum creatinine \>2 mg/dL. * Creatine phosphokinase (CPK) ≥5 x the upper limit of normal (ULN). * Hemoglobin ≤12 g/dL (120 g/L) for male subjects or ≤10 g/dL (100 g/L) for female subjects. * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2 x ULN. * Total bilirubin ≥1.5 x ULN. * Serum triglyceride concentration ≥400 mg/dL. * Subjects not using effective contraception methods (intra uterine device \[IUD\] and condom or diaphragm with spermicide and condom) during the study and for at least one month thereafter. * Pregnant, lactating, breastfeeding, or intends to become pregnant during the course of the study (females only). All women must have a negative urine pregnancy test at the Screening Visit, be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or have a postmenopausal status (no menses) for at least one year. * Contraindications to or known or suspected hypersensitivity to aspirin, simvastatin or ramipril or their excipients. * Presence of mental illness limiting the capacity for self-care. * Presence of major systemic illnesses: renal disease, liver disease, neurological or psychiatric disease. * Participation, in the 30 days preceding enrolment into the study, in any other clinical study in which investigational or marketed drugs were employed.